Brands
MTR Foods unveils new TVC highlighting its sub-brand Minute Range
Mumbai: Packaged food products company MTR Foods Pvt Ltd on Wednesday launched a digital film showcasing its MTR Minute Range of products. The film focuses on the hyper-convenience, time-saving and delicious proposition of the portfolio of products.
The film starts with a snapshot of a usual work-from-home day for a millennial who has ordered lunch in the middle of a busy day but is a little annoyed with the delay in promised delivery time. When she starts questioning the delivery person about the delay, he informs her about the hyper-convenient, delicious alternative to ordering food – the MTR Minute Range – with the signature hand gesture and the ‘ready in mmmm..minutes’ tag. The closure of the film is a showcase of MTR Minute Range that can satisfy any kind of food craving – from breakfast to lunch or dinner and even comfort food.
Sharing her thoughts on the campaign, MTR Foods GM of marketing Prerna Tiku said, “The millennials and gen-Z are the ‘now’ generation that is constantly on the lookout for hyper-convenience in everything they do. We recognised this need early on and pioneered many concepts to cater to these needs in the foods space and conceived of the MTR Minute Range. Through this film, we aim to raise awareness about the entire range, a perfectly crafted portfolio of products that offer the much-loved Indian taste in a hyper-convenient format across dayparts.”
The film will be distributed through various media outlets and will be supported by influencer marketing and social media contests, to reach a wider audience. The campaign will be targeted towards Delhi, Mumbai, Bangalore, and Hyderabad and goes live on 20 April.
The campaign is currently live across MTR Foods’ social media handles.
Brands
Sun Pharma to acquire Organon in $11.75 billion deal at $14 per share
Acquisition to create $12.4 billion pharma giant with global scale and biosimilars push
MUMBAI: Sun Pharmaceutical Industries Limited has signed a definitive agreement to acquire Organon & Co. in an all-cash deal valued at $11.75 billion, marking one of the largest cross-border pharma acquisitions by an Indian firm.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash, with Sun Pharma set to acquire 100 per cent of the company’s outstanding shares. The transaction, approved by the boards of both companies, is expected to close in early 2027, subject to regulatory approvals and shareholder consent.
The deal significantly expands Sun Pharma’s global footprint and strengthens its position across women’s health, biosimilars, and branded generics. The combined entity is projected to generate revenues of around $12.4 billion, placing it among the top 25 pharmaceutical companies globally.
Organon, which was spun off from Merck in 2021, brings a portfolio of over 70 products spanning women’s health and general medicines, with operations across more than 140 countries. Its established presence in key markets such as the US, Europe, and China complements Sun Pharma’s existing strengths and growth ambitions.
Sun Pharmaceutical Industries Limited executive chairman Dilip Shanghvi said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of reaching people and touching lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own.”
Sun Pharmaceutical Industries Limited managing director Kirti Ganorkar added, “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products.”
From Organon’s side, Organon & Co. executive chair Carrie Cox noted, “This all-cash transaction offers compelling and immediate value to Organon stockholders, while positioning the business for continued growth under Sun Pharma.”
Strategically, the acquisition gives Sun Pharma entry into the global biosimilars space as a top 10 player and strengthens its innovative medicines portfolio, which is expected to contribute around 27 per cent of combined revenues. The deal is also expected to nearly double EBITDA and cash flow, supporting long-term deleveraging and investment capacity.
Sun Pharma plans to fund the acquisition through a mix of internal accruals and committed financing from global banks, while maintaining focus on disciplined integration and operational continuity post-merger.
If completed as planned, the deal signals a clear shift in India’s pharmaceutical ambitions, from scale at home to leadership on the global stage, with Sun Pharma positioning itself as a more diversified and innovation-led healthcare powerhouse.
